Skip to main content

Celecoxib

ADVERTISEMENT
Identification
Molecular formula
C17H14F3N3O2S
CAS number
169590-42-5
IUPAC name
4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
State
State
Celecoxib is typically found in a solid powder form at room temperature. It is often manufactured for use in solid dosage forms like capsules.
Melting point (Celsius)
157.00
Melting point (Kelvin)
430.15
Boiling point (Celsius)
167.00
Boiling point (Kelvin)
440.15
General information
Molecular weight
381.37g/mol
Molar mass
381.3720g/mol
Density
1.5259g/cm3
Appearence

Celecoxib appears as a white crystalline powder. It is practically insoluble in water at physiological pH but soluble in some organic solvents. The powder form can easily clump up when exposed to humid conditions due to its crystalline nature.

Comment on solubility

Solubility of 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide (C17H14F3N3O2S)

The solubility of 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide can be influenced by several factors due to its complex structure. Here are some key points regarding its solubility:

  • Polarity: This compound contains both polar (e.g., amide and sulfonamide groups) and non-polar regions (e.g., the cyclohexyl moiety). This dual nature may lead to variable solubility in polar and non-polar solvents.
  • Solvent Interaction: The solubility may be higher in solvents like dichloromethane or dimethyl sulfoxide (DMSO), which can effectively interact with the polar sections of the molecule.
  • Functional Groups: The presence of several functional groups, including a carboxamide and a sulfonamide, contributes to the potential hydrogen bonding capabilities of the compound, enhancing solubility in aqueous environments.
  • Temperature Dependency: Like many organic compounds, its solubility could increase with temperature, making hot solvents preferable for dissolution.
  • Stability Implications: Solubility issues can affect the stability and efficacy of the compound in pharmaceutical applications, necessitating careful formulation considerations.

Understanding the solubility characteristics of this complex compound is vital for its application, especially in medicinal chemistry, where bioavailability often hinges on how well a compound dissolves in bodily fluids.

Interesting facts

Interesting Facts about 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide

This compound, known for its complex structure, has piqued the interest of chemists and researchers alike due to its potential applications and unique characteristics. Here are some noteworthy aspects:

  • Pharmacological Potential: This compound may have therapeutic applications, particularly in the field of medicinal chemistry. Its structural components suggest it could exhibit biological activity that warrants further exploration.
  • Complex Architecture: The intricate arrangement of functional groups, including a pyrrole ring and a sulfamoyl moiety, showcases the versatility of organic synthesis techniques. The careful design of these elements can lead to compounds with specific features and functions.
  • Synthesis Challenges: Due to its elaborate composition, the synthesis of this compound can be complex and requires meticulous planning and execution. Synthetic chemists often face challenges in obtaining desired yields and purities, making this an exciting target for innovation in reaction methodologies.
  • Role in Material Science: Compounds with such complex frameworks are often explored for their properties in material science, potentially contributing to advancements in polymers or nanomaterials.
  • Collaborative Research: The study of this compound often necessitates interdisciplinary collaboration between chemists, pharmacologists, and materials scientists to fully investigate its properties and potential uses.

As we continue to explore compounds like this, it's important to quote the famous chemist Linus Pauling who once said, "The best way to have a good idea is to have lots of ideas." Continuous research and development open doors to discovering new and exciting applications in the chemical world.

Synonyms
glimepiride
93479-97-1
Amaryl
cis-Glimepiride
Glimepirida
Amarel
Glimepirid
Glimepiridum
684286-46-2
Hoe-490
Glimepride
HOE 490
Glimepiride, cis-
Glimepiride Impurity A
CHEBI:5383
1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea
4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
MFCD00878417
Endial
261361-60-8
NSC-759809
24T6XIR2MZ
DTXSID5040675
6KY687524K
NCGC00016960-03
Glimepiridum [Latin]
Roname
Glimepirida [Spanish]
CAS-93479-97-1
Glista OD
1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-
3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
Ristomycin Monosulfate (90%)
DTXCID3020675
Glymepirid
Glorion
Glemax
Glimer
Solosa
Ristocetin Sulfate; Ristomycin Sulfate
1-[[4-[2-[[(3-Ethyl-4-methyl-2-oxo-2,3-dihydro-1H-pyrrol-1-yl)carbonyl]amino]ethyl]phenyl]sulphonyl]-3-(cis-4-methylcyclohexyl)urea (cis-Glimepiride)
3-Ethyl-4-methyl-N-(4-(N-((rel-(1r,4r)-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-N-{2-[4-({[(4-methylcyclohexyl)carbamoyl]amino}sulfonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
SMR000466368
SL-NH2 Trifluoroacetic Acid Salt (1:2)
Amaryl (TN)
CCRIS 7083
SR-05000001508
UNII-24T6XIR2MZ
boxamide
BRN 5365754
gimepiride
Niddaryl
Sugral
HOE490
UNII-6KY687524K
Glimepiride,(S)
Glimepiride [USAN:USP:INN:BAN]
Glimepiride; 3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl] 2-oxo-1H-pyrrole-1-carboxamide; Amaryl; Glimperide; HOE 490; trans-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl] 2-oxo-1H-pyrrole-1-carboxamide
Amaryl, Glista OD
Glimepiride (Standard)
CPD000466368
GLIMEPIRIDE [MI]
Prestwick0_000651
Prestwick1_000651
Prestwick2_000651
Prestwick3_000651
GLIMEPIRIDE [INN]
GLIMEPIRIDE [JAN]
GLIMEPIRIDE [USAN]
GLIMEPIRIDE [VANDF]
CHEMBL1481
GLIMEPIRIDE [MART.]
Oprea1_382896
SCHEMBL16084
SCHEMBL16086
BSPBio_000681
GLIMEPIRIDE [USP-RS]
GLIMEPIRIDE [WHO-DD]
GLIMEPIRIDE CIS-ISOMER
MLS000759495
MLS001076674
MLS001401419
MLS003915622
MLS006011260
SPBio_002602
GLIMEPIRIDE [EMA EPAR]
BPBio1_000751
CHEMBL149223
GTPL6820
SCHEMBL8738802
Glimepiride (JP18/USP/INN)
Glimepiride - Bio-X trade mark
SCHEMBL14371714
SCHEMBL14965363
SCHEMBL26496475
CHEBI:92609
HY-B0104R
DTXSID20861130
GLIMEPIRIDE [ORANGE BOOK]
Glimepiride for system suitability
GLIMEPIRIDE [EP MONOGRAPH]
GLIMEPIRIDE [USP IMPURITY]
HMS1570C03
HMS2052L03
HMS2090K18
HMS2097C03
HMS2235L07
HMS3269A09
HMS3372O07
HMS3394L03
HMS3413K06
HMS3654F17
HMS3677K06
HMS3714C03
Pharmakon1600-01504915
GLIMEPIRIDE [USP MONOGRAPH]
BCP05331
DRB80990
DUETACT COMPONENT GLIMEPIRIDE
HY-B0104
Tox21_110713
AC-476
BDBM50237590
NSC759809
NSC813217
s1344
STL451059
STL453194
AKOS015894919
AKOS015969663
Glimepiride, >=98% (HPLC), solid
Tox21_110713_1
AB07644
BCP9000728
CCG-101156
CS-1844
DB00222
FG23667
FG23668
KS-5238
NC00406
NSC 759809
NSC-813217
NCGC00016960-01
NCGC00016960-02
NCGC00016960-04
NCGC00016960-05
NCGC00016960-07
NCGC00161404-01
NCGC00161404-02
NCGC00181757-01
NCGC00371061-02
NCGC00371061-06
1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea
1H-Pyrrole-1-carboxamide, 2,5-dihydro-3-ethyl-4-methyl-N-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-
3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro
BG164507
SMR001550123
Glimepiride 100 microg/mL in Acetonitrile
AB00513874
CS-0165191
G0395
GLIMEPIRIDE IMPURITY A [EP IMPURITY]
NS00004860
SW196369-4
C07669
D00593
AB00513874-06
AB00513874-08
AB00513874-09
AB00513874_10
AB00513874_11
EN300-19873446
Q425027
SR-05000001508-1
SR-05000001508-2
SR-05000001508-3
BRD-K34776109-001-03-4
BRD-K34776109-001-14-1
BRD-K34776109-001-15-8
BRD-K34776109-001-16-6
BRD-K42693031-001-01-8
Q27253874
Z1501475009
Glimepiride, British Pharmacopoeia (BP) Reference Standard
Glimepiride, European Pharmacopoeia (EP) Reference Standard
3-ethyl-4-methyl-N-(4-(N-((1r,4r)-4-methylcyclohexylcarbamoyl)
Glimepiride, United States Pharmacopeia (USP) Reference Standard
sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
Glimepiride for system suitability, European Pharmacopoeia (EP) Reference Standard
1-((4-(2-(((3-ETHYL-4-METHYL-2-OXO-2,3-DIHYDRO-1H-PYRROL-1-YL)CARBONYL)AMINO)ETHYL)PHENYL)SULFONYL)-3-(CIS-4-METHYLCYCLOHEXYL)UREA
1H-PYRROLE-1-CARBOXAMIDE, 3-ETHYL-2,5-DIHYDRO-4-METHYL-N-(2-(4-(((((CIS-4-METHYLCYCLOHEXYL)AMINO)CARBONYL)AMINO)SULFONYL)PHENYL)ETHYL)-2-OXO-
1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(trans- 4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-
3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-2-oxo-N-(2-{4-[({[(1r,4r)-4-methylcyclohexyl]carbamoyl}amino)sulfonyl]phenyl}ethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-N-(4-(N-(((1r,4r)-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-N-(4-(N-(((1s,4s)-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide? (Glimepiride Impurity pound(c)
3-ETHYL-4-METHYL-N-(4-(N-((1R,4R)-4-METHYLCYCLOHEXYLCARBAMOYL)SULFAMOYL)PHENETHYL)-2-OXO-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE
3-ethyl-4-methyl-N-[2-(4-{[(4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-N-[2-(4-{[(cis-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-car
3-ethyl-4-methyl-N-[2-(4-{[(cis-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-car boxamide
3-Ethyl-4-Methyl-N-[2-(4-{[(Cis-4-Methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-Oxo-2,5-Dihydro-1h-Pyrrole-1-Carboxamide
cis-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(cis-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1- carboxamide
N'-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-N-(4-methylcyclohexyl)carbamimidic acid
N-[4-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)-ethyl]-benzenesulfonyl]-N'-4-methylcyclohexylurea
trans-1-(4-(2-(3-ethyl-4-Me-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamido)ethyl)phenylsulfonyl)-3-(4-methylcyclohexyl)urea
trans-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methyl cyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide
Trans-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide
trans-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole -1-carboxyamide;1-[[p-[2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl]sulfonyl]-3-(trans-4-methylcycloh
trans-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole -1-carboxyamide